Aziri B, Begic E, Jankovic S, Mladenovic Z, Stanetic B, Kovacevic-Preradovic T, Iglica A, Mujakovic A. Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events. ESC Heart Fail. 2023;10(3):1499–530.
Article PubMed PubMed Central Google Scholar
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9.
Article CAS PubMed Google Scholar
Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757–67.
Article CAS PubMed Google Scholar
Hage C, Michaelsson E, Linde C, Donal E, Daubert JC, Gan LM, Lund LH. Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction: a holistic proteomic approach. Circ Cardiovasc Genet. 2017. https://doi.org/10.1161/CIRCGENETICS.116.001633.
Elrakaybi A, Laubner K, Zhou Q, Hug MJ, Seufert J. Cardiovascular protection by SGLT2 inhibitors—Do anti-inflammatory mechanisms play a role? Mol Metab. 2022;64: 101549.
Article CAS PubMed PubMed Central Google Scholar
Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis K, Tousoulis D. The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents. Int Immunopharmacol. 2022;111: 109080.
Article CAS PubMed Google Scholar
Larsson SC, Butterworth AS, Burgess S. Mendelian randomization for cardiovascular diseases: principles and applications. Eur Heart J. 2023;44(47):4913–24.
Article PubMed PubMed Central Google Scholar
Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement. JAMA. 2021;326(16):1614–21.
Li J, Yu Y, Sun Y, Yu B, Tan X, Wang B, Lu Y, Wang N. SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study. Cardiovasc Diabetol. 2023;22(1):278.
Article CAS PubMed PubMed Central Google Scholar
Consortium GT. The GTEx consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369(6509):1318–30.
Vosa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, Kirsten H, Saha A, Kreuzhuber R, Yazar S, et al. Large-scale cis-and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53(9):1300–10.
Article CAS PubMed PubMed Central Google Scholar
Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman AK, Kalnapenkis A, Enroth S, Cozzetto D, Digby-Bell J, Marten J, et al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol. 2023;24(9):1540–51.
Article CAS PubMed PubMed Central Google Scholar
Said S, Pazoki R, Karhunen V, Vosa U, Ligthart S, Bodinier B, Koskeridis F, Welsh P, Alizadeh BZ, Chasman DI, et al. Genetic analysis of over half a million people characterises C-reactive protein loci. Nat Commun. 2022;13(1):2198.
Article CAS PubMed PubMed Central Google Scholar
Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658–65.
Article PubMed PubMed Central Google Scholar
Wang Q, Shi Q, Wang Z, Lu J, Hou J. Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma. BMC Med. 2023;21(1):377.
Article CAS PubMed PubMed Central Google Scholar
Shah S, Henry A, Roselli C, Lin H, Sveinbjornsson G, Fatemifar G, Hedman AK, Wilk JB, Morley MP, Chaffin MD, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun. 2020;11(1):163.
Article CAS PubMed PubMed Central Google Scholar
Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, Hartwig FP, Kutalik Z, Holmes MV, Minelli C, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2019;4:186.
Zuber V, Colijn JM, Klaver C, Burgess S. Selecting likely causal risk factors from high-throughput experiments using multivariable Mendelian randomization. Nat Commun. 2020;11(1):29.
Article CAS PubMed PubMed Central Google Scholar
MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A comparison of methods to test mediation and other intervening variable effects. Psychol Methods. 2002;7(1):83–104.
Article PubMed PubMed Central Google Scholar
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol. 2015;44(2):512–25.
Article PubMed PubMed Central Google Scholar
Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8.
Article CAS PubMed PubMed Central Google Scholar
Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304–14.
Article PubMed PubMed Central Google Scholar
Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985–98.
Article PubMed PubMed Central Google Scholar
Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125(1–2):279–84.
Article CAS PubMed Google Scholar
Bouras E, Karhunen V, Gill D, Huang J, Haycock PC, Gunter MJ, Johansson M, Brennan P, Key T, Lewis SJ, et al. Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis. BMC Med. 2022;20(1):3.
Article CAS PubMed PubMed Central Google Scholar
Steven S, Oelze M, Hanf A, Kroller-Schon S, Kashani F, Roohani S, Welschof P, Kopp M, Godtel-Armbrust U, Xia N, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370–85.
Article CAS PubMed PubMed Central Google Scholar
Aragon-Herrera A, Feijoo-Bandin S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, Costa Pereira TM, Garcia-Caballero T, Rodriguez-Segade S, Rodriguez J, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019;170: 113677.
Article CAS PubMed Google Scholar
Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, Ren J, Davies MJ. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32–7.
Article CAS PubMed Google Scholar
Iannantuoni F, MdM A, Diaz-Morales N, Falcon R, Banuls C, Abad-Jimenez Z, Victor VM, Hernandez-Mijares A, Rovira-Llopis S. The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes. J Clin Med. 2019. https://doi.org/10.3390/jcm8111814.
Article PubMed PubMed Central Google Scholar
Nakano D, Kawaguchi T, Tsutsumi T, Hayakawa M, Yoshio S, Koga H, Torimura T. Effects of SGLT2 inhibitor on tumor-releasing chemokines/cytokines in Hep3B and Huh7 cells. JGH Open. 2022;6(4):270–3.
Article PubMed PubMed Central Google Scholar
Bakhshi H, Varadarajan V, Ambale-Venkatesh B, Meyghani Z, Ostovaneh MR, Durda P, Wu CO, Tracy RP, Cushman M, Bluemke DA, et al. Association of soluble interleukin-2 receptor alpha and tumour necrosis factor receptor 1 with heart failure: the multi-ethnic study of atherosclerosis. ESC Heart Fail. 2020;7(2):639–44.
Article PubMed PubMed Central Google Scholar
Pellicori P, Zhang J, Cuthbert J, Urbinati A, Shah P, Kazmi S, Clark AL, Cleland JGF. High-sensitivity c-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovasc Res. 2020;116(1):91–100.
Article CAS PubMed Google Scholar
Li X, Peng S, Guan B, Chen S, Zhou G, Wei Y, Gong C, Xu J, Lu X, Zhang X, et al. Genetically determined inflammatory biomarkers and the risk of heart failure: a Mendelian randomization study. Front Cardiovasc Med. 2021;8: 734400.
留言 (0)